These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11218789)

  • 1. [Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor].
    Rasmussen S; Husted SE
    Ugeskr Laeger; 2001 Jan; 163(4):461-5. PubMed ID: 11218789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
    Zhao XQ; Théroux P; Snapinn SM; Sax FL
    Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
    Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
    Vorchheimer DA; Badimon JJ; Fuster V
    JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor.
    Okmen E; Ozen E; Uyarel H; Sanli A; Tartan Z; Cam N
    Jpn Heart J; 2003 Nov; 44(6):899-906. PubMed ID: 14711185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
    Harrington RA
    Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Goa KL; Noble S
    Drugs; 1999 Mar; 57(3):439-62. PubMed ID: 10193692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    Young JJ; Kereiakes DJ
    J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.
    Cannon CP; Weintraub WS; Demopoulos LA; Robertson DH; Gormley GJ; Braunwald E
    Am J Cardiol; 1998 Sep; 82(6):731-6. PubMed ID: 9761082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.